Why Bristol-Myers Is Soaring
In this video, health care analyst David Williamson discusses Bristol-Myers Squibb's big pop, words not often used in conjunction with a big pharma stock with a $70 billion market cap. Shares were up as much as 7% intraday, hitting decade-long highs for Bristol in advance of tonight's release of ASCO abstracts.
Investors may be excited for phase 1 data for Bristol's cancer drug nivolumab in conjunction with Yervoy for late-stage melanoma. While the data has yet to be released, the possibility of outsize clinical gains is present, as both drugs get the immune system to attack cancer in different ways.
Obamacare will undoubtedly have far-reaching effects. The Motley Fool's new free report "Everything You Need to Know About Obamacare" lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.
The article Why Bristol-Myers Is Soaring originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.